By Gary Gamerman
BIOCONTRACT SERVICES:
A Supplement to BPJ Volume 3, Issue 1 (January/February 2004)
Despite trepidations, bioprocess oursourcing has come a long way from its inception, which was born in necessity and regulatory fear. Based on primary research that Seraphim and Pharmsource conducted in 2002, the current market for biopharmaceutical manufacturing outsourcing (upstream and downstream production of bulk APIs, but excluding separately outsourced analytics, development, and other services) was $500 to $700 million with a projection to grow to $1.5 to $2.5 billion over the next five years…
Citation: Gamerman G. Virtual Biopharmaceutical Sourcing: Six Methods for Six Sigma Outsourcing. BioProcess J, 2004; 3(1, Suppl. 1): S13-20. https://doi.org/10.12665/BCS1.Gamerman
Posted online July 17, 2026